[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals: Prepared To Defend Their Dominance And Expand Their Expertise",
    "summary": "Vertex Pharmaceuticals (VRTX) is a top biotech pick, with strong earnings, diverse pipelines, and growth prospects. See here for more analysis.",
    "url": "https://finnhub.io/api/news?id=4766ed9208a49714ae88135ae979a6c2865bb012039bd8339932b5e463dfb78f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767139182,
      "headline": "Vertex Pharmaceuticals: Prepared To Defend Their Dominance And Expand Their Expertise",
      "id": 137945944,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192614371/image_2192614371.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals (VRTX) is a top biotech pick, with strong earnings, diverse pipelines, and growth prospects. See here for more analysis.",
      "url": "https://finnhub.io/api/news?id=4766ed9208a49714ae88135ae979a6c2865bb012039bd8339932b5e463dfb78f"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know",
    "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $453.74, marking a -1.31% move from the previous day.",
    "url": "https://finnhub.io/api/news?id=e9e361b107d33fc5d6aa3733212b0dbad02e6148f36b4c9989bdc119905cb3bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767135004,
      "headline": "Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know",
      "id": 137950459,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $453.74, marking a -1.31% move from the previous day.",
      "url": "https://finnhub.io/api/news?id=e9e361b107d33fc5d6aa3733212b0dbad02e6148f36b4c9989bdc119905cb3bc"
    }
  },
  {
    "ts": null,
    "headline": "Tracking Tweedy Browne Portfolio - Q3 2025 Update",
    "summary": "Read here for Tweedy Browne's latest 13F updates, top holdings like Ionis Pharma, and shifting investment strategies.",
    "url": "https://finnhub.io/api/news?id=f534de22c8b9f9812ab099225a3acf0a9cdfe2449a721143ff270eb7ffa1312d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767132693,
      "headline": "Tracking Tweedy Browne Portfolio - Q3 2025 Update",
      "id": 137945592,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160013511/image_1160013511.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Read here for Tweedy Browne's latest 13F updates, top holdings like Ionis Pharma, and shifting investment strategies.",
      "url": "https://finnhub.io/api/news?id=f534de22c8b9f9812ab099225a3acf0a9cdfe2449a721143ff270eb7ffa1312d"
    }
  },
  {
    "ts": null,
    "headline": "2 Growth Stocks to Buy For 2026 and Beyond",
    "summary": "Neither had a great year in 2025, but the future is looking bright.",
    "url": "https://finnhub.io/api/news?id=45953b193d425260d15672cee69167bcd920a9f7fce391ccc02f05a071570244",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767100800,
      "headline": "2 Growth Stocks to Buy For 2026 and Beyond",
      "id": 137940442,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Neither had a great year in 2025, but the future is looking bright.",
      "url": "https://finnhub.io/api/news?id=45953b193d425260d15672cee69167bcd920a9f7fce391ccc02f05a071570244"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals price target raised to $525 from $456 at Leerink",
    "summary": "Leerink raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $525 from $456 and keeps an Outperform rating on the shares. The firm cites an increase in its terminal growth assumption from 1% to 2%. Leerink is optimistic about the company’s revenue and pipeline prospects, which it expects to drive stock price performance. The firm would caveat that it projects higher investment spending growth than consensus models. Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level d",
    "url": "https://finnhub.io/api/news?id=e9f2c164ee3714fbbeae1ceef41967fc496397deb72e90f1d2d809bef04ef9f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767100234,
      "headline": "Vertex Pharmaceuticals price target raised to $525 from $456 at Leerink",
      "id": 137940443,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Leerink raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $525 from $456 and keeps an Outperform rating on the shares. The firm cites an increase in its terminal growth assumption from 1% to 2%. Leerink is optimistic about the company’s revenue and pipeline prospects, which it expects to drive stock price performance. The firm would caveat that it projects higher investment spending growth than consensus models. Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level d",
      "url": "https://finnhub.io/api/news?id=e9f2c164ee3714fbbeae1ceef41967fc496397deb72e90f1d2d809bef04ef9f7"
    }
  }
]